Images List Premium Download Classic

Pharmaceutically Acceptable Salts

Pharmaceutically Acceptable Salts-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Deuterated tic10
Concert Pharmaceuticals, Inc.
January 18, 2018 - N°20180016277

This invention relates to novel imidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one compounds, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions alone or in combination with other therapeutics in the treatment of diseases and conditions that are beneficially treated by administering an inducer of the gene ...
NEW Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
Scifluor Life Sciences, Inc.
January 18, 2018 - N°20180016276

The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described.
NEW Diaza-benzofluoranthrene compounds
Harbin Pharmaceutical Group Co., Ltd. General Pharmaceutical Factory
January 18, 2018 - N°20180016270

Disclosed are a series of diaza-benzofluoranthrene compounds. The present invention particularly relates to a compound represented by formula (i), pharmaceutically acceptable salts or tautomers thereof.
NEW Pharmaceutically Acceptable Salts Patent Pack
Download 794+ patent application PDFs
Pharmaceutically Acceptable Salts Patent Applications
Download 794+ Pharmaceutically Acceptable Salts-related PDFs
For professional research & prior art discovery
inventor
  • 794+ full patent PDF documents of Pharmaceutically Acceptable Salts-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Inhibitors of the renal outer medullary potassium channel
Merck Sharp & Dohme Corp.
January 18, 2018 - N°20180016263

The present invention provides compounds of formula (i); and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1. 1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt ...
NEW Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
Merck Sharp & Dohme Corp.
January 18, 2018 - N°20180016239

The present invention relates to compounds according to formula (i-1) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of rorgammat-mediated diseases or conditions.
NEW Low-dose stable formulations of linaclotide
Forest Laboratories Holdings Limited
January 18, 2018 - N°20180015139

The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
NEW Pharmaceutically Acceptable Salts Patent Pack
Download 794+ patent application PDFs
Pharmaceutically Acceptable Salts Patent Applications
Download 794+ Pharmaceutically Acceptable Salts-related PDFs
For professional research & prior art discovery
inventor
  • 794+ full patent PDF documents of Pharmaceutically Acceptable Salts-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Methods and compositions for improving cognitive function
The Johns Hopkins University
January 18, 2018 - N°20180015109

The invention relates to methods and compositions for improving cognitive function by using a combination of a synaptic vesicle protein 2a (sv2a) inhibitor and an acetylcholinesterase inhibitor (achei) or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In particular, it relates to the use of a combination of an sv2a inhibitor and an achei in treating a central ...
NEW Pyridinyl and fused pyridinyl triazolone derivatives
January 18, 2018 - N°20180015083

Or pharmaceutically acceptable salts thereof, wherein r1, r2, r3, and r4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of formula 1, to pharmaceutical compositions which contain them, and to their use for treating type i hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with btk.
NEW Pharmaceutical composition for the treatment of obesity
Intas Pharmaceuticals Ltd.
January 18, 2018 - N°20180015042

The present invention relates to a layered pharmaceutical composition comprising: a first layer of sustained-release bupropion or its pharmaceutically acceptable salts, a second layer of sustained-release naltrexone or its pharmaceutically acceptable salts, with pharmaceutically acceptable excipients, and an intermediate inert layer that provides a time-controlled disintegration to allow separation of two drug layers and maintain their physical integrity as a ...
Glycopeptides conjugates and uses thereof
Jawaharlal Nehru Centre For Advanced Scientific Research (jncasr)
January 11, 2018 - N°20180009848

Vancomycin conjugates of formula i, its stereoisomers, prodrugs, pharmaceutically acceptable salts, and metal coordination complexes thereof is described in the present disclosure. Further, the present disclosure relates to pharmaceutical compositions comprising vancomycin conjugates, its stereoisomers, prodrugs, pharmaceutically 10 acceptable salts, metal coordination complex thereof with one or more other pharmaceutical compositions or an antibiotic. The present disclosure also describes a process ...
Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
Merck Sharp & Dohme Corp.
January 11, 2018 - N°20180009828

The present invention provides bruton's tyrosine kinase (btk) inhibitor compounds according to formula (i), or pharmaceutically acceptable salts thereof, formula (i) or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of btk inhibitor compounds of formula i in the treatment of btk mediated disorders.
Furoquinolinediones as inhibitors of tdp2
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
January 11, 2018 - N°20180009822

Compounds of formula i and the pharmaceutically acceptable salts thereof are disclosed formula i. The variables x1, x2, and r1-4 are disclosed herein. The compounds are useful for treating cancer and related proliferative diseases. Pharmaceutical compositions containing compounds of formula i and methods of treatment comprising administering compounds of formula i are also disclosed.
Heterocyclic compounds as pi3k-y inhibitors
January 11, 2018 - N°20180009816

Or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of pi3k-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
Pharmaceutically Acceptable Salts Patent Pack
Download 794+ patent application PDFs
Pharmaceutically Acceptable Salts Patent Applications
Download 794+ Pharmaceutically Acceptable Salts-related PDFs
For professional research & prior art discovery
inventor
  • 794+ full patent PDF documents of Pharmaceutically Acceptable Salts-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Inhibitors of the renal outer medullary potassium channel
Merck Sharp & Dohme Corp.
January 11, 2018 - N°20180009807

The present invention provides compounds of formula i (i) and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1. 1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive ...
(r)-2-methyl-piperazine derivatives as cxcr3 receptor modulators
January 11, 2018 - N°20180009800

Wherein r1 and r2 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the cxcr3 receptor.
Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
January 11, 2018 - N°20180009799

Wherein n, x, r1 and r2 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the cxcr3 receptor.
An improved process for the preparation of hcv inhibitor
Granules India Limited
January 11, 2018 - N°20180009790

The present invention provides a novel process for the preparation of ledipasvir of formula i and its pharmaceutically acceptable salts.
Inhibitors of trka kinase
Gvk Biosciences Private Limited
January 11, 2018 - N°20180009781

The present invention is directed to the compounds of formula i which are inhibitors of tropomyosin-related kinase a (trka): formula (i) or steroisomers, tautomers or a pharmaceutically acceptable salts, metabolites, isotopes, solvates or prodrugs thereof, wherein, ra, rb, rc, rd, r1, r2, l and het-ar are as defined herein. These compounds can be used for the preventive and/or therapeutic ...
Piperidine and azepine derivatives as prokineticin receptor modulators
Takeda Pharmaceutical Company Limited
January 11, 2018 - N°20180009780

The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof (formula (i)) in which m, x, r1, r2, r3 and r5 are as defined in the specification, processes for their preparation, pharmaceutical compositions n containing them and their use in therapy.
Pyrimidone compounds used as lp-pla2 inhibitors and pharmaceutical compositions thereof
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences
January 11, 2018 - N°20180009766

The present invention relates to pyrimidone compounds used as lp-pla2 inhibitors and pharmaceutical compositions thereof. The structure of the pyrimidone compounds is represented by general formula (i), wherein r1, r2, r3, x, ar, y and n are defined as in the specification and claims. The compounds of general formula (i) in the present invention, stereoisomers and pharmaceutically acceptable salts thereof ...
Oral topical aqueous pharmaceutical compositions of flurbiprofen and dexpanthenol
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
January 11, 2018 - N°20180008712

The present invention relates to stable oral topical aqueous pharmaceutical compositions comprising flurbiprofen or pharmaceutically acceptable salts thereof and dexpanthenol or pharmaceutically acceptable salts thereof. Furthermore the present invention also relates to stable oral topical aqueous pharmaceutical compositions comprising flurbiprofen or pharmaceutically acceptable salts thereof and dexpanthenol or pharmaceutically acceptable salts thereof and chlorhexidine or pharmaceutically acceptable salts thereof. More ...
Loading